Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$775.56 USD

775.56
3,712,121

-30.50 (-3.78%)

Updated Nov 6, 2024 11:48 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Lilly (LLY) COVID-19 Antibody Gets FDA Nod for Use in Kids

by Zacks Equity Research

With the approval in children and infants, Lilly's (LLY) bamlanivimab with etesevimab can now be given as treatment and prevention options to high-risk individuals of any age.

Merck (MRK) Up as COVID Pill Gets FDA Panel's Positive Vote

by Zacks Equity Research

An FDA committee voted 13-0 to recommend authorization of Merck's (MRK) antiviral pill to treat COVID-19.

Mark Vickery headshot

Top Research Reports for Mastercard, Pfizer & Nike

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), Pfizer Inc. (PFE), and NIKE, Inc. (NKE).

Merck (MRK) COVID Pill Less Effective in Final Study, Stock Down

by Zacks Equity Research

Merck's (MRK) new data from a phase III study shows its COVID-19 antiviral pill is less effective than previously reported.

Lilly (LLY) Up 4.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biogen's (BIIB) Aducanumab Gets CHMP's Negative Trend Vote

by Zacks Equity Research

Biogen's (BIIB) regulatory application seeking approval for its Alzheimer's drug, Aduhelm, in Europe hits setback as it receives negative trend vote from the CHMP.

Glaxo (GSK), Vir to Supply COVID Drug Sotrovimab to Government

by Zacks Equity Research

Glaxo (GSK) and Vir Biotechnology (VIR) sign purchase contract with the U.S. government to supply doses of sotrovimab worth approximately $1 billion by next month.

The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer and Novo Nordisk

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer and Novo Nordisk

Pfizer (PFE) Seeks FDA's Emergency Use Nod for COVID Pill

by Zacks Equity Research

Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially in mild-to-moderate COVID-19 patients at increased risk of hospitalizations or death.

Kinjel Shah headshot

3 Big Pharma Outperformers to Watch Out For in the Near Term

by Kinjel Shah

Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.

Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PJP

Glaxo (GSK), Vir Intramuscular Sotrovimab Meets Study Endpoint

by Zacks Equity Research

Glaxo (GSK) and Vir announce non-inferiority of intramuscular administration of sotrovimab compared to intravenous administration in reducing hospitalization or death as an early treatment of mild-to-moderate COVID-19.

Biogen (BIIB) Up on New Data From Phase III Studies on Aduhelm

by Zacks Equity Research

Biogen's (BIIB) Aduhelm significantly lowers plasma p-tau-181, a pathological hallmark of Alzheimer's disease, in phase III studies.

Merck (MRK) Inks $1.2B COVID-19 Pill Supply Deal With Japan

by Zacks Equity Research

Japan's government is set to purchase 1.6 million courses of Merck's (MRK) oral pill for COVID-19, molnupiravir, if approved or authorized.

Biohaven (BHVN) Misses on Q3 Earnings, Inks $1.24B Pfizer Deal

by Zacks Equity Research

Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. The company signs an agreement with Pfizer, granting the latter ex-U.S. marketing rights to Nurtec ODT.

Radius (RDUS) Q3 Loss Wider Than Expected, Stock Declines

by Zacks Equity Research

Radius (RDUS) reports a year-over-year wider Q3 loss and misses on sales. The company also lowers guidance for lead drug Tymlos.

Pfizer (PFE) COVID Pill Shows Strong Efficacy, Stock Rallies

by Zacks Equity Research

Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially

Should iShares MSCI USA Min Vol Factor ETF (USMV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for USMV

Nektar (NKTR) Q3 Earnings Top, Pipeline Remains On Track

by Zacks Equity Research

Nektar (NKTR) reports mixed third-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.

United Therapeutics (UTHR) Q3 Earnings & Sales Beat, Stock Up

by Zacks Equity Research

United Therapeutics (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.

Novo Nordisk's (NVO) Q3 Earnings and Sales Beat Estimates

by Zacks Equity Research

Novo Nordisk (NVO) reports better-than-expected results for Q3. Sales are aided by growth in Diabetes and Obesity Care owing to higher GLP-1 revenues.

PFE vs. LLY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

PFE vs. LLY: Which Stock Is the Better Value Option?

Amgen (AMGN) Q3 Earnings Top, Sales View Tightened, Stock Down

by Zacks Equity Research

Amgen (AMGN) beats Q3 estimates for both earnings and sales. It lowers the upper end of the sales guidance for 2021 while raising the earnings range.

Incyte (INCY) Q3 Earnings & Sales Beat, Royalty Revenues Grow

by Zacks Equity Research

Incyte (INCY) beats earnings and sales estimates in the third quarter on higher royalty revenues and increased Jakafi sales.

The Zacks Analyst Blog Highlights: Alphabet, Eli Lilly, Sony, American Express and Southern Company

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Alphabet, Eli Lilly, Sony, American Express and Southern Company